Literature DB >> 6831406

Cellular pharmacology of 3'-(4-morpholinyl) and 3'-(4-methoxy-1-piperidinyl) derivatives of 3'-deaminodaunorubicin in human colon carcinoma cells in vitro.

J B Johnston, R I Glazer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831406

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  5 in total

1.  Comparative effects of doxorubicin and 4'-epi-doxorubicin on nucleic acid metabolism and cytotoxicity in a human tumor cell line.

Authors:  O Cantoni; P Sestili; F Cattabeni; C Geroni; F Giuliani
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Synthesis and antitumor activity of a platinum (II)-doxorubicin complex.

Authors:  F Zunino; G Savi; A Pasini
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells.

Authors:  D G Streeter; J S Johl; G R Gordon; J H Peters
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.

Authors:  M Bakker; J P Droz; A R Hanauske; J Verweij; A T van Oosterom; H J Groen; M A Pacciarini; L Domenigoni; F van Weissenbruch; E Pianezzola; E G de Vries
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

5.  A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.

Authors:  E Fokkema; J Verweij; A T van Oosterom; D R Uges; R Spinelli; O Valota; E G de Vries; H J Groen
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.